Last week’s #OncFive:
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm

www.onclive.com/view/the-onc...

The @fda.gov granted fast track designation to the PSMA x CD3 T-cell engager VIR-5500 for the treatment of patients with late-line metastatic castration-resistant prostate cancer #pcsm #oncology

Read more: www.onclive.com/view/vir-550...

The addition of the anti-CD105 antibody carotuximab to apalutamide improved PFS vs apalutamide alone in mCRPC #pcsm #oncology

Check out the data and how they are shaping the ongoing phase 2 study: www.onclive.com/view/carotux...

Now enrolling! Dr. Deepak Kilari from @MedicalCollege is now enrolling @ALLIANCE-org A032302, the ASPIRE trial to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. To learn more, visit http://bit.ly/AllianceA032302. #clinicaltrials #PCSM

The addition of the ATR inhibitor berzosertib to carboplatin failed to boost responses vs carboplatin with/without docetaxel in heavily pretreated mCRPC #pcsm #oncology

Dive into the phase 2 data here: www.onclive.com/view/berzose...

Phase 2 and 3 data showed aglatimagene besadenovec plus EBRT was associated with improved prostate cancer–specific disease-free survival and evidence of sustained immune activity in intermediate-risk localized prostate cancer #pcsm #oncology

www.onclive.com/view/aglatim...

🔎 What happens after a cancer screening result comes back positive, but cancer isn’t found?

Jason Hafron, MD, of @oaklandu.bsky.social, discusses the often-overlooked burden of false positives and the need for more precise screening. #pcsm #oncology

Read more: www.onclive.com/view/calcula...

Just over a week ago, we welcomed our newest cohort to PCSM💙

From making new connections to taking their first steps towards a career in medicine, Welcome Week was full of exciting and memorable experiences.

#PCSM #FutureDoctors #WelcomeWeek #MedicalSchoolLife #StudentExperience #CumbriaMedicine

Drs. Rana McKay of UC San Diego and Misha Meltran Dana-Farber co-lead Alliance A032102/PREDICT evaluating if genetic testing helps determine the best treatment regimen for men with metastatic prostate cancer. Learn more: https://bit.ly/Alliance-A032102 #PCsm

Not all metastatic hormone-sensitive prostate cancers behave the same. New research shows baseline ctDNA tumor fraction before ADT initiation may help identify patients at higher risk for worse outcomes.

Read the article. https://bit.ly/4cucn2r
#ProstateCancer #pcsm

Dr. Brad McGregor of Dana-Farber leads Alliance A032201 (STRIKE) to see if adding the anti-cancer drug tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCI #NCTN #PCSM